ATLANTA, Sept. 17, 2018 /PRNewswire/ -- Alimera Sciences,
Inc. (NASDAQ: ALIM) (Alimera), a leader in commercialization and
development of prescription ophthalmic pharmaceuticals, today
announced that nine clinical presentations from real world
ILUVIEN® usage in Europe and the U.S. will be presented during
the 18th European Society of Retina Specialists Congress
(EURETINA), September 20-23, 2018, in
Vienna, Austria. There will also
be 15 electronic poster presentations highlighting the real-world
data available throughout the meeting for review by EURETINA
attendees.
On Friday, September 21, Alimera
will sponsor a symposium as part of the
EuroTimes Satellite Education Program. The lunchtime
event entitled "CONTINUOUS MICRODOSING with ILUVIEN: Optimizing the
Treatment of Persistent or Recurrent DME," will be moderated by
Francesco Bandello from University Vita-Salute, Ospedale San
Raffaele of Milan.
Panel participants include: Manuel
Falcao from University of Porto, Porto,
Portugal; Javier
Zarranz-Ventura from Institut Clínic d´Oftalmologia at
Hospital Clínic, Barcelona, Spain;
and Albert Augustin, from Karlsruhe
Klinikum, Karlsruhe, Germany.
The scheduled times and titles of the nine speaker presentations
are as follows (all times local Vienna time):
Thursday, September 20
- A. Augustin, GERMANY
The first report comparing the 3-year outcomes of ILUVIEN
(fluocinolone acetonide) in vitrectomised and non-vitrectomised
eyes in patients with DME – results from the RETRO-IDEAL study,
9:54 a.m.
- C. Pavesio, UK
The first European presentation of the safety and efficacy outcomes
with the 0.18 mg fluocinolone acetonide implant (FAc) for the
treatment of non-infectious posterior segment uveitis (NIU-PS) - 12
month interim analyses from an ongoing 36 month trial, 11:30 a.m.
- R. Khoramnia, GERMANY
Injectable 0.19 mg fluocinolone acetonide intravitreal implant for
the treatment of non-infectious uveitic macular edema, 11:36 a.m.
Friday, September 21
- U. Chakravarthy, UK
Does the duration of chronic diabetic oedema influence the
effectiveness and safety outcomes achieved in patients treated with
ILUVIEN (fluocinolone acetonide)? Clinical insights from the
ILUVIEN registry safety study, 3:18
p.m.
- C. Bailey, UK
3-year results of a UK multi-centre audit of electronic medical
records assessing real-world effectiveness and safety of ILUVIEN
190 micrograms intravitreal implant, 3:54
p.m.
- J. Zarranz-Ventura, SPAIN
Assessing the effectiveness of fluocinolone acetonide (0.2 µG/D
FAc) and dexamethasone (DEX 700 µG) steroid implants in phase III
pivotal trials using the area under the curve (AUC) method: The
CONSTANT analysis, 4:36 p.m.
Sunday, September 23
- S. Vaz-Perrera, PORTUGAL
The outcomes of switching from a short-term to long-term
intravitreal corticosteroids implant therapy in patients with
diabetic macular edema (DME), 9:06
a.m.
- A. Eaton, U.S.A.
Realworld outcomes in the US following the use of the fluocinolone
acetonide (FAc) 0.19 mg (ILUVIEN) implant in patients with diabetic
macular edema: The results from the USER study, 10:42 a.m.
- A. Kotagiri, UK
Malposition of fluocinolone acetonide implants in patients with
diabetic macular oedema: A possible cause of reduced efficacy,
10:54 a.m.
About ILUVIEN
U.S. website www.ILUVIEN.com
ILUVIEN'S U.S. Indication
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is
a sustained release intravitreal implant approved in the U.S. to
treat diabetic macular edema in patients who have been previously
treated with a course of corticosteroids and did not have a
clinically significant rise in intraocular pressure. Each ILUVIEN
implant is designed to release submicrogram levels of fluocinolone
acetonide, a corticosteroid, for up to 36 months.
ILUVIEN'S E.U. Indication
ILUVIEN is indicated for the treatment of vision impairment
associated with chronic diabetic macular oedema, considered
insufficiently responsive to available therapies.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic
retinopathy, is a disease affecting the macula, the part of the
retina responsible for central vision. When the blood vessel
leakage associated with diabetic retinopathy results in swelling of
the macula, the condition is called DME. The onset of DME is
painless and may go unreported by the patient until it manifests
with the blurring of central vision or acute vision loss. The
severity of this blurring may range from mild to profound loss of
vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy
found that over a 10-year period approximately 19% of people with
diabetes included in the study were diagnosed with DME. All people
with type 1 or type 2 diabetes are at risk of developing DME.
About Alimera Sciences, Inc.
www.alimerasciences.com
Alimera Sciences (NASDAQ:ALIM), founded in June 2003,
is a pharmaceutical company that specializes in the
commercialization and development of prescription ophthalmic
pharmaceuticals. Alimera is presently focused on diseases affecting
the back of the eye, or retina, because these diseases are not well
treated with current therapies and will affect millions of people
in our aging populations. Alimera's commitment to retina
specialists and their patients is manifest in Alimera's product
portfolio. For more information, please
visit www.alimerasciences.com.
For press
inquiries:
Katie
Brazel
for Alimera
Sciences
404-317-8361
kbrazel@bellsouth.net
|
|
For investor
inquiries:
CG Capital
for Alimera Sciences
877-889-1972
investorrelations@cg.capital
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/alimera-sciences-announces-nine-clinical-presentations-and-a-sponsored-symposium-at-18th-euretina-congress-300713892.html
SOURCE Alimera Sciences, Inc.